Novo Nordisk has provided diabetes treatment to over 5.5 million underserved patients as of 2022
Globally, type 1 diabetes affects more than 1.2 Mn young people under the age of 20, with 184,100 new cases every year4. Diabetes is 17% more prevalent in rural areas2. In these areas, children lack access to insulin, and blood glucose monitoring, and are often misdiagnosed by doctors2,3,4. Diabetes is the 7th leading cause of death in the US5. Despite this, the country's insulin cost is the highest (USD 98.7) among 32 countries6.
Novo Nordisk is a global provider of diabetic drugs9. In 2022, it has extended access to diabetes treatment goods to over 5.5 Mn individuals through its access and affordability initiatives, constituting ~15% of the 36.3 Mn people reached by its diabetic drugs14;p7.
In 2009, Novo Nordisk launched the "Changing Diabetes® in Children" program in partnership to help children in low and medium-income areas who are dealing with type 1 diabetes1. The program provides free medicines, and equipment to children up to 25 years old12,4. As of 2022, it established 360+ diabetic clinics in rural areas and provided over 24,000 healthcare personnel with training on type 1 diabetes in children4. It also donated over 3.8 Mn vials, pens, or cartridges, benefitting 41,000+ children in 26 countries4.
In the US, Novo Nordisk provided $37 billion in sales discounts and rebates in 2022, amounting to 75% of its US gross sales14;p16. An example of this is the Patient Assistance Program (PAP), through which it provided free insulin to 63,000 diabetic patients in the US who have an annual household income at or below 400% of the poverty level14;p16. Studies show that PAP members are 30% less likely to quit insulin11.
Further, the Novo Nordisk Haemophilia Foundation, in partnership, has helped diagnose and re-test over 44,800 people in low and middle-income countries with haemophilia (a rare blood disease), and trained 57,200 professionals (2005-2023)15,14;p95.
Novo Nordisk has facilitated access to healthcare & training to over 5.5 Mn underserved people.
Actual Direct Impact
Rate the quality in this analysis
How objective, relevant and insightful is this analysis?
Share this Analysis
Keen to rectify an issue with this analysis?
Report issue
There is no comment yet.